Diverse Nrf2 activators (antroquinonol, osthole, citral, or astaxanthin) were nephroprotective in experimental models of FSGS by reducing ROS production, and increasing HO-1, GPX4, and Nrf2 activity [207,208,209,210]. The gene discussed is NFE2L2; the disease is focal segmental glomerulosclerosis.